A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF NIVOLUMAB OR NIVOLUMAB PLUS CISPLATIN, IN COMBINATION WITH RADIOTHERAPY IN PARTICIPANTS WITH CISPLATIN INELIGIBLE AND CISPLATIN ELIGIBLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)

Registry ID
CA209-9TM
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE3
Study type
INTERVENTIONAL
Sponsor
BRISTOL-MYERS SQUIBB CANADA
Start date
2018-09-10
Last update
2018-03-09

Conditions

Related clinical trials

View on source registry